First-in-class phage-probiotic symbiotic
Cognitive Restoration via the Gut-Brain Axis
Targeting the root cause of age-related memory loss by removing the pathogenic gut-brain signal identified in Cox et al., Nature (2026).
PARTNERSHIP INQUIRIES
First-in-class phage-probiotic symbiotic
Targeting the root cause of age-related memory loss by removing the pathogenic gut-brain signal identified in Cox et al., Nature (2026).
PARTNERSHIP INQUIRIES
Decades of amyloid-focused R&D have produced near-zero disease-modifying therapies.
Sources: WHO (2025), Alzheimer's Disease International, GBD/Lancet Public Health (2022), Cummings et al. (2022)
Gram-negative anaerobe overrepresented in the aged gut
▶Capric and caprylic acid enter systemic circulation
▶Receptor signaling triggers IL-1β neuroinflammation
▶Memory impairment via vagal-mediated inflammation
Lytic bacteriophages specifically targeting P. goldsteinii deplete the pathogenic microbe without disrupting commensal flora.
Bifidobacterium longum, released from MCFA-mediated suppression, recolonizes and restores gut barrier integrity and SCFA production.
Thermal Shield™ formulation (trehalose / Eudragit S100 spray-dried matrix) ensures phage viability through manufacturing and GI transit. Patent pending.
Vagal Bio sits at the convergence: a gut-derived, neuroscience-backed therapeutic in the longevity space.
Cox et al. 2026 found that GLP-1 receptor signaling opposes GPR84-mediated damage on vagal neurons. GLP-1 agonists push the protective signal; Vagal Bio removes the damaging one.
Push the protective signal (GLP-1R activation on vagal afferents).
Novo Nordisk, Eli Lilly, Amgen
Remove the damaging signal (P. goldsteinii MCFA → GPR84 depletion).
First-in-class phage-probiotic
GLP-1 pushes the signal. Vagal Bio removes the brake.
We're seeking licensing partners, co-development collaborators, and seed investment to build the first gut-brain cognitive therapeutic.
